Rovadicitinib

Just days after deepening ties with one partner in China, AstraZeneca has inked an agreement with another of the country's pharmaceutical companies, this time through a collaboration with Sino Biopharmaceutical. The deal — announced Wednesday — is focused on Sino Biopharm's experimental PDE3/4 inhibitor TQC3721. Under the agreement, AstraZeneca will pay $200 million upfront for exclusive rights to develop, manufacture and commercialise TQC3721 outside of China. In addition, Sino Biopharm is eligible to receive further milestones, totalling up to $1.9 billion, as well as tiered sales royalties ranging up to double-digit percentages.Sino Biopharm noted that by inhibiting both PDE3 and PDE4, the therapy is designed to deliver synergistic bronchodilatory and anti-inflammatory effects, with the potential to improve lung function, reduce exacerbations and address broader disease burden in patients with chronic respiratory diseases. In a Phase IIb study, a nebulised formulation of TQC3721 demonstrated, what the Chinese firm called, "a potential best-in-class profile" for chronic obstructive pulmonary disease.The nebulised formulation of TQC3721 is currently being evaluated in a Phase III study in China, while a dry powder inhaler version is also being advanced in a Phase II trial. Sino Biopharm said that the pact with AstraZeneca will accelerate the global clinical development of TQC3721, whilst maximising its potential clinical and commercial value. As part of the deal, the UK drugmaker will also gain exclusive global rights to certain future development programmes. Last week, AstraZeneca unveiled its fourth collaboration with CSPC Pharmaceutical, betting nearly $1.8 billion on the Chinese firm's siRNA drug discovery platform for renal diseases. The two first joined forces in 2024, with a second agreement following last year before a mammoth obesity and type 2 diabetes-focused deal potentially worth up to $18.5 billion was signed this past January.Meanwhile, Wednesday's agreement marks Sino Biopharm's second out-licensing transaction with a big pharma player this year, coming hot on the heels of an agreement with Sanofi for the experimental oral JAK/ROCK inhibitor rovadicitinib.

AstraZeneca has secured ex-China rights to TQC3721, an inhaled dual PDE3/4 inhibitor for COPD, in a deal worth USD 200 million upfront and up to USD 2.1 billion in total potential value. The molecule, discovered and developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), a subsidiary of Hong Kong-listed Sino Biopharmaceutical Limited (HKEX: 1177), has generated Phase IIb data in COPD and is currently in Phase III in China. The deal is the second major out-licensing transaction CTTQ has executed in 2026, following Sanofi’s acquisition of global rights to rovadicitinib in a deal worth up to USD 1.53 billion in March. Under the agreement, AstraZeneca receives an exclusive license to develop, manufacture, and commercialize TQC3721 outside China. AstraZeneca also gains exclusive global rights for certain future CTTQ development programs — a forward-looking provision that adds pipeline optionality beyond the core single-asset structure. CTTQ retains full China rights and continues independent development of both the nebulized formulation (currently in Phase III) and a dry powder inhaler formulation (in Phase II). The deal is subject to customary closing conditions including regulatory clearances. Milestones of up to USD 1.9 billion span development, regulatory, and sales triggers; specific breakdowns were not disclosed. Royalties are tiered and reach up to double-digit percentages on annual net sales. TQC3721 is a small molecule inhaled dual PDE3/4 inhibitor. By simultaneously blocking PDE3 and PDE4, the molecule is designed to produce bronchodilatory effects — historically associated with PDE3 inhibition — alongside anti-inflammatory activity driven by PDE4 inhibition, in a single inhaled agent. Phase IIb data in COPD were presented at the European Respiratory Society congress in September 2025, where the nebulized formulation demonstrated a profile described by the company as potentially best-in-class. TQC3721’s most direct competitive reference point is ensifentrine (Ohtuvayre), a nebulized PDE3/4 inhibitor developed by Verona Pharma that received US FDA approval in June 2024 and was subsequently acquired by Merck for USD 10 billion in 2025. GSK licensed a competing Chinese-originated inhaled PDE3/4 inhibitor, HRS-9821 from Hengrui Pharma, as part of a broader 12-program deal in July 2025 worth up to USD 12 billion in aggregate. That deal makes HRS-9821 TQC3721’s most direct clinical competitor, with both assets originating from Chinese developers, both licensed ex-China to top-three global respiratory companies, and both targeting COPD with the same dual mechanism. AstraZeneca has been executing a systematic Chinese asset acquisition strategy across modalities in 2026. The company paid a USD 1.2 billion upfront payment to CSPC Pharmaceutical under a long-acting peptide collaboration, and separately entered a collaboration with CSPC for siRNA candidates targeting renal disease worth up to USD 1.77 billion. The TQC3721 transaction extends that pattern into respiratory, a therapeutic area where AstraZeneca’s existing franchise — anchored by Breztri (budesonide/glycopyrrolate/formoterol) and the anti-TSLP biologic tezepelumab — does not include an approved PDE3/4 inhibitor. The addition of TQC3721 would occupy a mechanistically distinct niche from both AstraZeneca’s existing inhaled triple combination and its biologic respiratory assets. For Sino Bio, the deal is the third announced partnership with a top-five global pharmaceutical company in under three months in 2026 — Sanofi in March, GSK (for bepirovirsen commercialization in China and, on the same day as this announcement, for Trelegy Ellipta and Anoro Ellipta commercialization rights in mainland China), and now AstraZeneca. That sequencing is deliberate: each deal increases CTTQ’s negotiating leverage and public credibility as a preferred partner for multinational respiratory and specialty pharma companies operating in or out of China. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Privacy Terms About Us Copyright © 2026. AllSci Corp. All rights reserved.